Prosecution Insights
Last updated: October 02, 2026
Application No. 18/683,162

AQUEOUS PERSONAL CARE COMPOSITIONS COMPRISING CARBOXYMETHYL CELLULOSE (CMC), PROCESS FOR PREPARING THE SAME AND USE THEREOF

Final Rejection §103§DOUBLEPATENT
Filed
Feb 12, 2024
Priority
Aug 13, 2021 — provisional 63/232,760 +2 more
Examiner
KIM, DANIELLE A
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Isp Investments LLC
OA Round
2 (Final)
37%
Grant Probability
At Risk
3-4
OA Rounds
10m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allowance Rate
36 granted / 97 resolved
-22.9% vs TC avg
Strong +56% interview lift
Without
With
+56.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
77 currently pending
Career history
179
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
70.0%
+30.0% vs TC avg
§102
5.6%
-34.4% vs TC avg
§112
15.9%
-24.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 97 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application was filed 12 February 2024 and is the national stage entry of PCT/US/22/38489 filed 27 July 2022. The Applicant claims priority to provisional application 63/232,760 filed 13 August 2021. The effective filing date of the instant application is 13 August 2021. Examiner’s Note The Applicant's amendments and arguments filed 06 July 2026 are acknowledged and have been fully considered. The Examiner has re-weighed all the evidence of record. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. In the Applicant’s response, filed 06 July 2026, it is noted that claims 1, 3-6, 10, 13-20 have been amended, claims 2, 7-9 have been canceled, and no new claims have been added. Support for the amendments can be found from the canceled claims. No new matter has been added. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 3-6, 10, 13-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Konno et al. (US 2012/0207689 A1), Dijk et al. (US 2008/0071077 A1), CMC document (2021), Anton Paar (2020), and Nouryon (2020). Konno teaches a hair care composition (abs; entire teaching) that may comprise CMC as a semi-synthetic macromolecule (para. 48) in an amount of 5% (Table 14), wax (para. 59), water (para. 123), coconut oil (para. 60), silicones and dimethicones (para. 67), and additives, such as magnesium stearate, in an amount of 1% (paras. 58, 88, Table 1), addressing claims 10, 15-17, and partially claim 1. The formulation may be gels, creams, and emulsions (para. 122), addressing claim 14. Other ingredients include xanthan gum (para. 47), acrylate polymers and copolymers (para. 49), modified starch (para. 44), cationized guar gum derivatives (para. 103), and thickeners (para. 17), addressing claims 3-5, 13, and 20. The composition may be used impart hair smoothness (para. 311), addressing claim 18. The pH of the composition may be in the range of 7-12 (para. 33), addressing claim 19. Konno does not specifically teach using low-substituted CMC in claim 1, CMC as a dry powder in claim 6, a combination of the ingredients in claim 1, or the viscosity and molecular weight in claim 1. Dijk teaches that CMC with a degree of substitution of at least 0.6 (para. 26) is suited for hair care products, such as shampoo (para. 11). Nouryon teaches that CMC is typically used as a dry powder (pg. 23). In regards to selecting the combination of CMC, water, and polymers in claim 1 “[w]hen a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious.” KSR v. Teleflex, 127 S.Ct. 1727, 1740 (2007) (quoting Sakraida v. A.G.Pro, 425 U.S. 273, 282 (1976)). “When the question is whether a patent claiming the combination of elements of prior art is obvious,” the relevant question is “whether the improvement is more than the predictable use of prior art elements according to their established functions.” (Id.). Addressing the issue of obviousness, the Supreme Court noted that the analysis under 35 USC 103 “need not seek out precise teachings directed to the specific subject matter of the challenged claim, for a court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ.” KSR at 1741. The Court emphasized that “[a] person of ordinary skill is… a person of ordinary creativity, not an automaton.” Id. at 1742. Consistent with this reasoning, it would have been obvious to have selected various combinations of various disclosed ingredients from within a prior art disclosure, to arrive at compositions “yielding no more than one would expect from such an arrangement.” Konno teaches a hair care composition that may comprise CMC, whereas the claimed invention is directed towards a composition comprising low-substituted CMC, at least one personal care additive, and water Since Konno teaches the individual components of the claimed composition, it is obvious for one of ordinary skill in the art to select the different combinations of ingredients to arrive at the claimed invention with a reasonable expectation of success. Since Konno does not specifically teach using low-substituted CMC in claim 1 or CMC as a dry powder in claim 6, one of ordinary skill in the art would have been motivated to use Dijk’s teaching of low-substituted CMC with a DS of around 0.6 and Nouryon’s teaching of CMC as a dry powder with a reasonable expectation of success. Dijk teaches that CMC with a DS of at least 0.6 is preferably suited for hair care products. A skilled artisan would have recognized the benefit of adding lower-substituted CMC to Konno’s composition, especially because the CMC document that lower-substituted CMC is more thixotropic (pg. 2) and Anton Paar teaches that thixotropic formulations are better for hair care products (pg. 1). Additionally, since Nouryon teaches that CMC is typically used as a dry powder, it is obvious to a skilled artisan that the CMC used in Konno’s could also be used as a dry powder. “Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use (see MPEP § 2144.07).” Regarding the amount of additives in claim 11, Dijk also teaches mineral oil and wheat germ oil in amounts of 4% and 2%, respectively (Examples 4 and 6). Additionally, in regards to the viscosity and molecular weight in claims 7 and 8, Dijk teaches a viscosity of over 12,000 mpa.s in a 1% aqueous solution (para. 33) with a DP of 6500 and DS of 0.75. However, Dijk specifically teaches a DS of at least 0.6 (para. 26). Therefore, the molecular weight of CMC with a DS of 0.6 and DP of 6500 may be expected to be around 1,365,000 Daltons (MW = DP x (162+80(DS)) (Nouryon, pg. 10). That being said and in lieu of objective evidence of unexpected results, the amounts, viscosity, and molecular weight can be viewed as a variable that achieves the recognized result of successfully making the low-substituted CMC composition, which a skilled artisan would have been easily motivated to modify and adjust. The optimum or workable range of amounts, viscosity, and molecular weight can be accordingly characterized as routine optimization and experimentation (see MPEP 2144.05 (II)B). “[Discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” In re Boesch, 617 F.2d 272, 276 (CCPA 1980). Applicants provide no evidence of any secondary consideration such as unexpected results that would render the optimized viscosity and molecular weight as nonobvious. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 3-6, 10, 13-18, 20 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12, 16-18 of copending Application No. 18/554,377 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1 and 16 recite low-substituted CMC, at least one additive, and water with a degree of substitution of 0.5 to about 0.7, which correspond to instant claim 1. Claims 2-4 include polymers that are similar to instant claims 3-5 and 13. Claim 5 recites CMC as a powder, which corresponds to instant claim 6. Claims 6 and 7 recite the same viscosity and molecular weight ranges as instant claim 1. Claims 9 and 17 recite an emulsion formulation and instant claim 14 recites an emulsion formulation. Claim 10 recites a gel, body lotion, cream, etc., which also corresponds to instant claim 14. Claim 11 recites imparting certain properties to the consumer, which corresponds to instant claim 18. Claim 12 recites a hair care product, shampoo, conditioner, etc., which corresponds to instant claim 10. Claim 18 recites additives, which corresponds to additives similar to instant claims 15-17 and 20. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Double Patenting Arguments The Examiner confirms the typographical error and the correct Application No. in regards to the Double Patenting rejection is 18/554,377. The Applicant has requested the above double-patenting rejections be held in abeyance until patentable subject matter is identified. In response, in any future response the Applicant must address the double patenting grounds of rejection, either by presenting arguments why the rejection is not applicable or by the filing of a terminal disclaimer. The Applicant is required to reply to every ground of rejection in the prior office action per 37 CFR 1.111(b). It is noted that only claim objections or requirements as to form not necessary to further considerations of the claims may be requested to be held in abeyance until allowable subject matter is indicated. Applicant is cautioned that further requests to hold this rejection in abeyance will not be considered responsive; such a request does not comply with CFR 1.111 (b). Response to Arguments Applicant's arguments filed 06 July 2026 have been fully considered but they are not persuasive. The Applicant argues that Dijk’s examples direct a person of ordinary skill in the art away from the claimed DS range and does not motivate a skilled artisan to select the range (Remarks, pgs. 8-9). Applicant’s argument is not found persuasive. The Applicant is erroneously pointing to narrow embodiments expressly disclosed within the prior art reference as representing the sum total of information conveyed by each. Art is art, not only for what it expressly teaches, but also for what it would reasonably suggest to the skilled artisan, including alternative or non-preferred embodiments (see MPEP § 2123). Furthermore, in response to the Applicant's argument that the references fail to show certain features of applicant’s invention, it is reminded that to properly teach away, the prior art reference must criticize, discredit, or otherwise discourage the solution sought. Merely teaching alternatives does not do this (see MPEP 2145 (X)(D)). The Applicant argues that the cited references do not cure the deficiencies of Konno and Dijk (Remarks, pg. 9). Applicant’s argument is not found persuasive. Since Konno does not specifically teach using low-substituted CMC in claim 1 or CMC as a dry powder in claim 6, one of ordinary skill in the art would have been motivated to use Dijk’s teaching of low-substituted CMC with a DS of around 0.6 and Nouryon’s teaching of CMC as a dry powder with a reasonable expectation of success. Dijk teaches that CMC with a DS of at least 0.6 is preferably suited for hair care products. A skilled artisan would have recognized the benefit of adding lower-substituted CMC to Konno’s composition, especially because the CMC document that lower-substituted CMC is more thixotropic (pg. 2) and Anton Paar teaches that thixotropic formulations are better for hair care products (pg. 1). Additionally, since Nouryon teaches that CMC is typically used as a dry powder, it is obvious to a skilled artisan that the CMC used in Konno’s could also be used as a dry powder. “Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use (see MPEP § 2144.07).” The Applicant argues that the proposed combination requires impermissible hindsight (Remarks, pgs. 9-10). Applicant’s argument is not found persuasive. It must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). The Applicant argues that the recited parameters are not subject to routine optimization (Remarks, pg. 10). Applicant’s argument is not found persuasive. Regarding the amount of additives in claim 11, Dijk also teaches mineral oil and wheat germ oil in amounts of 4% and 2%, respectively (Examples 4 and 6). Additionally, in regards to the viscosity and molecular weight in claims 7 and 8, Dijk teaches a viscosity of over 12,000 mpa.s in a 1% aqueous solution (para. 33) with a DP of 6500 and DS of 0.75. However, Dijk specifically teaches a DS of at least 0.6 (para. 26). Therefore, the molecular weight of CMC with a DS of 0.6 and DP of 6500 may be expected to be around 1,365,000 Daltons (MW = DP x (162+80(DS)) (Nouryon, pg. 10). That being said and in lieu of objective evidence of unexpected results, the amounts, viscosity, and molecular weight can be viewed as a variable that achieves the recognized result of successfully making the low-substituted CMC composition, which a skilled artisan would have been easily motivated to modify and adjust. The optimum or workable range of amounts, viscosity, and molecular weight can be accordingly characterized as routine optimization and experimentation (see MPEP 2144.05 (II)B). “[Discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” In re Boesch, 617 F.2d 272, 276 (CCPA 1980). Applicants provide no evidence of any secondary consideration such as unexpected results that would render the optimized viscosity and molecular weight as nonobvious. Furthermore, the adjustment of particular conventional working conditions (e.g., determining result effective amounts of the ingredients beneficially taught by the cited references, especially within the broad ranges instantly claimed), is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Accordingly, this type of modification would have been well within the purview of the skilled artisan and no more than an effort to optimize results. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Danielle Kim whose telephone number is (571)272-2035. The examiner can normally be reached M-F: 9-5 p.m. PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached at (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D.A.K./Examiner, Art Unit 1613 /ANDREW S ROSENTHAL/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Feb 12, 2024
Application Filed
Mar 03, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Jul 06, 2026
Response Filed
Aug 19, 2026
Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734193
AMMONIUM CHLORIDE FORMULATION TO SUPPORT HUMAN NATURAL DEFENSE AGAINST VIRUSES
4y 9m to grant Granted Sep 15, 2026
Patent 12728081
SUNSCREEN FORMULATION
2y 7m to grant Granted Sep 08, 2026
Patent 12714671
CELL MEMBRANE LIPID-EXTRACTED NANOPARTICLES (CLENS) FOR SELECTIVE TARGETING, IMAGE ANALYSIS AND CANCER THERAPY
5y 7m to grant Granted Aug 25, 2026
Patent 12691073
Coated Solid Preparation
5y 4m to grant Granted Jul 28, 2026
Patent 12678535
MULTILAYER VASCULAR GRAFT
5y 4m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
37%
Grant Probability
93%
With Interview (+56.3%)
3y 5m (~10m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 97 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month